Skip to main content

Table 3 Weight and BMI changes reported in selected LAI publications

From: Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations

LAI(s) used Reference n Weight change, mean difference, kg BMI change, mean difference, kg/m2
Risperidone [15] 715 1.4*** 0.5***
Various [48] 293 0.0a NR
Various [52] 176 0.1 NR
Various [53] 540 2.9b 0.7b
Various [55] 1173 NR 0.2b
Various [58] 2399 −1.0b NR
Various [61] 534 1.3c NR
Perphenazine [78] 42 No weight changed NR
Risperidone [79] 192 0.0 −0.1
Risperidone [85] 1476 0.9 0.3
Risperidone [86] 202 0.5 0.2
Various [88] 565 0.9* NR
Risperidone [90] 249 1.4*** 0.5***
Risperidone [105] 336 2.5 0.8
Risperidone [108] 50 NR 0.0
Various [112] 97 NR 1.5b
Risperidone [132] 67 −0.3 NR
Risperidone [133] 529 1.0*** 0.6***
Various [134] 5950 NR −0.7e
  1. Abbreviations: BMI = body mass index; LAI = long-acting injectable antipsychotic drugs; NR = not reported; pts = patients.
  2. aPts treated with in-range chlorpromazine-equivalent doses versus patients treated with higher chlorpromazine-equivalent doses.
  3. bVersus oral antipsychotics.
  4. cPts treated with LAI and anticholinergic drugs versus patients treated with LAI without anticholinergic drugs.
  5. dThis study reported no weight change, with 16 pts gaining a range of 1-9 kg and 7 pts losing a range of 1-2 kg.
  6. ePatients achieving persistent remission versus patients with prolonged disease.
  7. *p ≤ .05; ** p ≤ .01; ***p ≤ .001.